This clinical trial evaluates the effects of exercise therapy on signs of colorectal cancer in colon tissue and blood in people who completed pelvic radiation therapy for prostate cancer. People who get radiation in the pelvic area have a higher chance of developing colon cancer years later. This is because radiation can cause new mutations and inflammation. Research shows that exercise lowers colon cancer risk by about 30%. The results of this trial may help researchers better understand how exercise affects the development of colorectal cancer in patients who were treated with pelvic radiation therapy for prostate cancer.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07790718.
Locations matching your search criteria
United States
California
Duarte
City of Hope Comprehensive Cancer CenterStatus: Active
Contact: Gregory Idos
Phone: 626-228-4207
Irvine
City of Hope at Irvine LennarStatus: Approved
Contact: Gregory Idos
Phone: 626-228-4207
PRIMARY OBJECTIVE:
I. Determine the effects of exercise on mitigating molecular features in collected normal mucosa sample and any polyps identified.
SECONDARY OBJECTIVES:
I. Study longitudinal changes in predictors of colon cancer risk.
II. Evaluate accrual and retention rates, as well as exercise compliance and safety.
EXPLORATORY OBJECTIVES:
I. Bank tissue from standard of care colonoscopies/flex sigmoidoscopies for exploratory biological analyses (e.g., immune cell infiltration, mutational signature analysis).
II. Explore associations between baseline gut microbiome composition and baseline exercise exposure (continuous Godin Leisure Time Exercise Questionnaire [GLTEQ] score), as well as changes in gut microbiome composition following the 6-month exercise intervention
OUTLINE:
STAGE 1: Patients undergo standard of care (SOC) colonoscopy/flex sigmoidoscopy with tissue biopsy and complete a survey. Patients determined to have low exercise behaviors (less than 60 minutes/week of moderate and/strenuous exercise in the last 30 days) may proceed to Stage 2.
STAGE 2: Patients participate in individualized walking sessions over 10-70 minutes each, 5 times per week (225 minutes total per week), for 6 months. Patients also undergo collection of a blood sample on study and undergo SOC colonoscopy/flex sigmoidoscopy with tissue biopsy during follow-up.
After completion of study intervention, patients are followed up within 2 weeks, or up to 3 months, for completion of follow-up SOC colonoscopy/flex sigmoidoscopy.
Trial PhaseNo phase specified
Trial Typesupportive care
Lead OrganizationCity of Hope Comprehensive Cancer Center
Principal InvestigatorGregory Idos